Is an HPV test better than a Pap smear for cervical cancer screening? What to know as Ontario shifts guidelines
This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Contact a qualified medical professional before engaging in any physical activity, or making any changes to your diet, medication or lifestyle.
Ontario is the latest province to change how it screens for cervical cancer. Starting March 3, healthcare providers will be replacing Pap smears with human paoillomavirus (HPV) testing. According to Ontario Health, HPV testing is a more accurate method for detecting cervical cancer, which means people could be tested less frequently.
Previously, B.C. and P.E.I. announced plans to adopt HPV testing as the primary method of cervical cancer screening. Quebec began a gradual transition to HPV tests in 2023 with the goal of replacing Pap smears in 2025. In July 2024, Nova Scotia announced it's intention to switch to HPV testing, but it would take approximately two years before Pap smears would be replaced.
In B.C., eligible patients can request an at-home screening kit that includes a vaginal swap which can be sent by mail to be processed. Ontarians will still need to visit a healthcare provider to receive an HPV test, since at-home tests are not part of the current roll out.
Cervical cancer is a sexually transmitted disease.Dr. Kim Alexander
In a previous interview with Yahoo Canada, Ontario-based gynecologist Dr. Kim Alexander said that roughly 95 per cent of cervical cancers are caused by HPV: "Cervical cancer is a sexually transmitted disease … so if we know your HPV status, we actually know your level of risk."
With HPV testing, she added "we can actually know whether you have the virus that causes cancer. That's super powerful." Moreover, HPV testing is essentially more accurate than Pap smears, and they can now be done faster than before.
The Canadian Medical Association Journal stated: "Pap testing has a high specificity of 96.8 per cent but a low sensitivity (55.4 per cent), which means that screening misses almost half of existing abnormalities."
A Papanicolaou test, also known as a Pap smear or Pap test, checks for abnormal cervical cells which could lead to cancer if left untreated, but they don't test for HPV itself. An HPV test, however, screens for high-risk types of HPV that could cause pre-cancers of the cervix. Neither test actually detects cancer — only abnormalities or high-risk strains of HPV.
Alexander said HPV testing comes positive on average 15 years before a cancer develops. A Pap test may never become positive — even if a person has the virus.
"The false rate of Pap test is in the range of 10 to 20 per cent, so we can miss things on the Pap test. ... HPV testing missing rate is close to zero. … It's very effective in determining your risk," Alexander noted.
Both tests are performed by taking a swab of the cervix to obtain a sample of cervical cells which are then sent for testing. Usually, these tests are tests are performed by a doctor or nurse who may insert a speculum to open the vagina to access the cervix. Some people may feel discomfort or a slight cramp during the process and may experience light bleeding afterwards, but the swab can be obtained very quickly.
Health Canada outlined HPV is one of the most common sexually transmitted infections (STIs) in the country — and worldwide. There are more than 100 types of HPV, most of which cause no symptoms and go away on their own. Some types, however, can infect areas such as the hands and feet, according to the federal agency.
"Other types target the anogenital area and are transmitted during vaginal, or oral sex or during intimate skin-to-skin contact with someone who is infected," Health Canada noted.
HPV causes almost all cervical cancers but is also linked to cancer of the throat, oral cavity, penis, anus, vagina or vulva. Moreover, it's possible to be infected by more than one type of HPV at a time, according to Health Canada. It estimated as many as 75 per cent of sexually active men and women will have at least one type of HPV infection in their lifetime.
According to Alexander, HPV testing is done in a similar way to a Pap smear, where a swab gets used to collect a small sample of cells from a cervix or vagina that may have the cancer-causing virus.
In Canada, HPV testing may not be covered by a provincial or territorial health program, and people may have to pay for it out-of-pocket.
Alexander described Ontario's current process: "If my patient gets a funny Pap test, I can actually call into the lab and ask them to run an HPV [test] on it."
"Or, I can check a box when I submit that Pap specimen that says please run HPV at this time. ... And because we really want to get a good idea about their ongoing risk, most of my patients do agree to pay the $100 that it cost to process their HPV test," she added.
Unlike the Pap test, which requires a cytopathologist to detect precancerous cervical cells, testing of a cervical sample for HPV subtypes uses polymerase chain reaction (PCR), the Canadian Medical Association Journal explained.
"One of the bonuses of implementing [HPV testing] now is that the machines we're using are the same machines that they used for COVID," Alexander explained.
"That's actually going to help speed up implementation."
Because HPV testing is able to catch problems so early, Alexander said it only needs to be done every five years, in comparison with the three years recommendation of Pap smears.
"The awesome thing about HPV testing is that it gives you a risk before you might even be developing a problem. ... Ideally, we're going to see that HPV test changed to negative for most people who get the virus," she explained.
For most people the virus is going to be a minor blip in their life.Dr. Kim Alexander
Alexander added 80 per cent of people will clear the virus from their body within two years, especially patients in their 20s: "Most people are not going to get cancer. For most people, the virus is going to be a minor blip in their life … but at some point as we get older, that gets more challenging."
Alexander said cervical cancer "is a vaccine preventable disease." The vaccine is generally available for kids in school and for people up to the age of 26, but people who are older can get it too.
The HPV vaccine commonly used is the HPV9 vaccine, also known as Gardasil 9. This vaccine protects against nine different types of HPV and protects against seven types that can cause cancers of the cervix, anus, mouth and throat, penis, vagina and vulva, and two types that can cause genital warts.
At-risk people include those who:
Have had genital warts
Have had abnormal Pap tests
Have frequent new sexual partners
The vaccine is also recommended for people who are in midlife too, aged 40 and up.
"Doctors and non-doctors have stereotypes about who's at risk, and that married people are not at risk for acquiring the HPV virus," Alexander shared.
Midlife vaccination is something to consider.Dr. Kim Alexander
"But midlife relationship instability is so common, like divorce, affairs and those who decide to have non-monogamous relationships, which can put people in midlife at risk."
Unlike younger people who have a higher chance of clearing the virus, only 60 per cent of people in their 40s clear it within two years.
"This is why midlife vaccination is something to consider ... because the virus is just there for longer, with more ability to cause problems for people," Alexander added.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
5 hours ago
- Business Wire
HekaBio, Japan-based Biopharma and MedTech Platform, Enters Strategic Partnership with Alfresa Holdings Corporation
TOKYO--(BUSINESS WIRE)--HekaBio K.K. (Headquarters: Chuo-ku, Tokyo; President & CEO: Robert E. Claar; hereinafter 'HekaBio') today announced the signing of a strategic partnership agreement with Alfresa Holdings Corporation (Headquarters: Chiyoda-ku, Tokyo; Representative Director & President: Ryuji Arakawa; hereinafter 'Alfresa Holdings'), the leading pharmaceutical wholesaler group in Japan. As part of this agreement, Alfresa Holdings has also made a capital investment in HekaBio. The partnership aims to accelerate the commercialization of innovative medical products in Japan. HekaBio, Japan-based Biopharma and MedTech Platform, Enters Strategic Partnership with Alfresa Holdings Corporation -- Accelerating Access to Innovative Therapies in Japan through Alfresa Group's 'Total Supply Chain Service'-- Share Background and Purpose In recent years, Japan has implemented policy reforms to address the growing access gap, where innovative therapies approved overseas are slow to come to the Japanese market. In response to these developments, HekaBio has focused on introducing cutting-edge pharmaceuticals, medical devices, and regenerative medicine products from global markets into Japan and the Asia-Pacific markets. Leveraging a proprietary global network and partnership model, HekaBio evaluates over 200 assets annually across oncology, cardiology and CNS, and supports end-to-end commercialization from licensing to clinical and regulatory development, manufacturing and sales. This partnership with Alfresa Group will enable HekaBio to advance and expand its portfolio and impact, particularly in CNS and regenerative medicine where Alfresa Group has strengths in manufacturing and in sales, including various other aspects of sales-related operations across the supply chain. Outlook Through this partnership, HekaBio and Alfresa Group aim to accelerate the introduction of high-impact, potential blockbuster therapies into the Japanese market, expanding treatment options for patients. The companies also plan to explore commercialization strategies across the Asia-Pacific region and beyond. About HekaBio HekaBio is a Japan-based, asset-light healthcare platform that accelerates patient access to global medicines and MedTech across Asia-Pacific. HekaBio reviews over 200 assets annually to in-license a select few, focusing on early-stage, de-risked opportunities in CNS, oncology, and healthy longevity. HekaBio synchronizes U.S. and Japan development timelines and leverages strategic partnerships to optimize commercial success. Japan, the world's third-largest healthcare market, serves as its launchpad for regional expansion. To learn more about HekaBio's mission and portfolio, visit About Alfresa Holdings Alfresa Holdings is the holding company for the Alfresa Group, which operates businesses ranging from the development, manufacture, and distribution of pharmaceuticals to the operation of dispensing pharmacies and is the top corporate group in Japan in terms of ethical pharmaceuticals wholesaling, with consolidated net sales exceeding ¥2.9 trillion in the fiscal year ended March 31, 2025. Guided by its corporate philosophy, 'we create and deliver a fresh life for all,' the entire Group supports supply chains for pharmaceuticals and other products, a form of social infrastructure underpinning Japanese healthcare, contributing to a wide range of medical needs. For more information:
Yahoo
5 hours ago
- Yahoo
OCEU/CUPE 1750 Awaiting Employer Response as Talks Continue
TORONTO, June 16, 2025--(BUSINESS WIRE)--The Ontario Compensation Employees Union (OCEU/CUPE 1750) spent the weekend in mediated negotiations with the Workplace Safety and Insurance Board (WSIB) and remains focused on reaching a fair deal that addresses the serious workload and mental health crisis facing frontline staff. The union is awaiting a response from the employer and expects further communication on Monday. "We've been in talks with the mediator and are standing by, ready to continue bargaining," said Harry Goslin, President of OCEU. "We've done our part to keep things moving and are hopeful the employer will respond promptly so we can make meaningful progress." The union emphasized that the situation remains urgent, with workloads and wages still at the core of the dispute. The Ford government's involvement in setting wage mandates has also made it harder to reach agreement, while the employer continues to push for regressive language that would worsen working conditions. This weekend's negotiations came just days after the release of a troubling new follow-up survey showing WSIB staff are experiencing anxiety and depression at twice the national average, results that reflect a growing mental health crisis. The independent survey, conducted by the Occupational Health Clinics for Ontario Workers (OHCOW), found that workloads, toxic management, and denial from leadership are fueling burnout across the organization. "These conditions are harming not only staff, but also the injured workers who depend on us," said Harry. "Despite it all, our members continue to show up, speak up, and push for real change." OCEU/CUPE 1750 remains committed to a fair settlement and restoring services for the people of Ontario. As the strike continues into its fourth week, all picket lines across cities in Ontario will remain active. mb/cope491 View source version on Contacts For more information, please contact: Bill ChalupiakCUPE Communications Representativewchalupiak@ 416-707-1401 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Business Insider
10 hours ago
- Business Insider
I bring healthcare to people's homes in Singapore. AI is changing home care, but it can't replace clinicians.
This as-told-to essay is based on a conversation with Dr. Shravan Verma, the cofounder and CEO of Speedoc, a Singapore-based health tech startup. This interview has been edited for length and clarity. As someone who has worked in both tertiary hospitals as well as some underserved environments, I saw the opportunity to create a virtual hospital that brings healthcare directly to where patients are, starting with their homes. Why should access to hospital-grade care be dependent on geography or infrastructure? The home will become the new center of care, and AI will be the invisible infrastructure enabling this shift. With AI software becoming more sophisticated and AI-enabled hardware becoming more accessible, care will become more personalized. I see the future of home care as a hybrid, with AI-enabled self-care tools integrated into regulated, human-involved systems. Singapore and the region are more ready than we think. In Singapore, we're already seeing strong policy alignment and public trust in digital systems. Even the patient mindset is maturing around receiving care outside traditional hospitals. Embedded AI AI is already a foundational layer of our operations. Our command center uses AI to triage patient cases, optimize our logistics for clinician dispatch, and even anticipate escalation risks. For example, AI models continuously analyze data from devices like pulse oximeters, BP monitors, or even passive sensors. If a patient's vitals begin trending dangerously, clinicians are alerted before deterioration sets in. We've prevented emergency room visits this way. The next phase is using AI for predictive care, orchestration, preempting deterioration in chronic patients, automating routine follow-ups, and eventually building an AI copilot for our clinicians. Clinicians expect systems to support and not slow down their work. Our nurses and doctors are asking for tools that reduce admin burden, triage smarter, and give them more actionable insights. Patients, too, are increasingly comfortable with these digital touchpoints, but they do want these to feel personalized and intelligent. Clinicians will be transformed, not replaced, by AI AI will transform but not replace the clinician role, especially in home settings. Their role becomes more relational as AI simplifies documentation and supports better decision-making. AI can't replicate the presence, empathy, and nuanced judgment in uncertain or complex conditions. It can't speak with family and understand what's best for the patient. AI can tell you — worst case — you're having a heart attack, but then what do you do about it? I know the diagnosis of a heart attack, but I need to be sent immediately to a hospital, make sure that I get stented, and get the catheterization, which is still very human-driven. Somebody also has to ensure continuity, ensure the administration of treatments and follow-ups, and ensure that the patients are improving as they're supposed to. Many of the conditions we treat at home also require IV drips, IV antibiotics, blood tests, and urine tests. Lead with outcomes, not AI Chatbots and AI tools can handle the first mile of care, but they must escalate to qualified professionals when needed. We need to be vigilant about bias in training data and sometimes a lack of contextual nuances in understanding what a patient's condition is. One of the key challenges with AI is confabulation, which is AI coming up with analysis or data that didn't exist for the patient. Governance, transparency, and auditability must be baked into every AI deployment. When it comes to AI-driven home care, the key is not to lead with AI but with outcomes and convenience. Patients don't really ask, "Is this AI?" They ask, "Is this faster, safer, more personalized?" When AI helps a patient get triaged within minutes or enables a nurse to show up at the right time with the right medication, that builds confidence. The real unlock is making sure AI remains transparent, empathetic, and always augments, not replaces, the human touch.